Indivior (INDV)
(Delayed Data from NSDQ)
$7.46 USD
-0.52 (-6.52%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $7.44 -0.02 (-0.27%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.46 USD
-0.52 (-6.52%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $7.44 -0.02 (-0.27%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth A Momentum B VGM
Zacks News
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Rigel (RIGL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Addex Stock Soars on Crucial Update From Indivior Research Deal
by Zacks Equity Research
ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.
Indivior PLC (INDV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Indivior (INDV) delivered earnings and revenue surprises of 10% and 4.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Stevanato Group (STVN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Stevanato (STVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Indivior (INDV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 12th
by Zacks Equity Research
CSIQ, FMC and INDV have been added to the Zacks Rank #5 (Strong Sell) List on July 12, 2024.
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
by Zacks Equity Research
Indivior (INDV) slashes financial guidance for 2024, primarily to reflect adverse sales conditions of its top-selling opioid drug. It will discontinue the sales of its schizophrenia drug.
Indivior PLC (INDV) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Indivior (INDV) delivered earnings and revenue surprises of -2.63% and 5.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Indivior (INDV) Surges 5.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Indivior (INDV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Indivior PLC (INDV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Indivior PLC (INDV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia
by Zacks Equity Research
Vanda's (VNDA) supplemental new drug application seeking approval for Hetlioz to treat insomnia gets a complete response letter from the FDA.
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
by Zacks Equity Research
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move.
Zacks.com featured highlights Modine Manufacturing, Indivior and Interface
by Zacks Equity Research
Modine Manufacturing, Indivior and Interface have been highlighted in this Screen of The Week article.
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
by Zacks Equity Research
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
3 Must-Buy Efficient Stocks to Strengthen Your Portfolio
by Santanu Roy
Invest in companies like Modine Manufacturing (MOD), Indivior (INDV) and Interface (TILE) that are powered by higher efficiency levels.
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
by Zacks Equity Research
Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.
Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates
by Zacks Equity Research
Puma Biotechnology's (PBYI) fourth-quarter 2024 earnings and revenues fall shy of estimates. Stock declines.
Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Mirum's (MIRM) earnings fall shy of estimates in the fourth quarter of 2023 while revenues beat the same.
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
by Zacks Equity Research
Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.
Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks
by Zacks Equity Research
Novavax's (NVAX) fourth-quarter earnings and revenues miss estimates. Stock tanks on moderate revenue guidance for 2024.
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
by Zacks Equity Research
Acadia's (ACAD) fourth-quarter earnings miss estimates while revenues beat the same. Higher product sales drive year-over-year revenues. Shares fall in after-hours trading.
Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates
by Zacks Equity Research
Apellis' (APLS) fourth-quarter 2023 bottom line misses estimates, while the top line meets the same. The newly approved product, Syfovre, drives year-over-year sales.
Neurocrine (NBIX) Soars 6.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Neurocrine (NBIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Indivior PLC (INDV) Loses -17.71% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Indivior PLC (INDV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.